IgG4-related ophthalmic disease (IgG4-ROD) is a common manifestation of IgG4-related disease, but its clinicopathologic features and the mechanisms underlying fibrosis remain incompletely understood. We retrospectively analyzed 100 cases of IgG4-ROD and investigated fibrosis using immunohistochemistry for IgG4, FOXP3, CD68, and CD163, together with RNA in situ hybridization for TGFB1. IgG4-ROD was histologically categorized into four patterns (Patterns 1-4) reflecting progressive fibrosis, demonstrating a spectrum from lymphoplasmacytic inflammation to marked fibrosis. Fibrosis was absent or minimal in 51% of cases, indicating that fibrosis is not essential for diagnosis, whereas obliterative phlebitis was rare. Compared with non-fibrotic cases, fibrotic cases showed significantly increased numbers of CD68-positive and CD163-positive macrophages (p < 0.001), predominantly localized at the interface between lymphoid and fibrotic areas. In contrast, fibrosis was not associated with IgG4-positive plasma cells, FOXP3-positive regulatory T cells, or EBV status. TGFB1 expression was significantly higher in lymphocyte-rich than fibrotic areas (p < 0.001), suggesting a closer association with lymphocyte-rich inflammation than established fibrosis. These findings demonstrate progressive histologic changes from Pattern 1 to Pattern 4 and suggest that accumulation of CD163-positive macrophages is associated with fibrosis in IgG4-ROD.
BACKGROUND:Breast phyllodes tumours (PT) are rare biphasic neoplasms consisting of epithelial and stromal components. They are classified into benign, borderline and malignant categories. Diagnosing and grading PTs present a challenge for pathologists, as there are multiple histological parameters and their own tiers. We aim to investigate the potential role of artificial intelligence (AI) as a diagnostic aid in determining PT grade. MATERIALS AND METHODS:We investigated 15 PT whole slide images (WSIs), comprising 5 benign, 5 borderline and 5 malignant cases. We sought to classify and retrieve the most relevant WSIs by matching histological features at different patch sizes, using the Yottixel framework for WSI processing. Patches were extracted at a 20× magnification level. We then used the KimiaNet to extract feature vectors and transformed these into barcode representations. Barcodes of a query WSI were compared with those of others in the archive, allowing us to identify the most similar WSI and determine the PT grades from histological similarities. RESULTS:We utilized 'majority-n accuracy' as a measure of correctness, that is when the majority of the top-n search results have the correct diagnosis as the query patient. We achieved a maximum reported accuracy of 67%, with a 3000 × 3000 patch size when grading PT at majority voting with n = 4. CONCLUSION:Despite the small sample size and absence of fine-tuning, our study demonstrated the potential of AI-based PT grade stratification using various patch sizes through histological matching. This serves as a preliminary proof of concept, with the prospect of refinement for potential routine clinical application.
Abstract Purpose: Gastrointestinal tumors, including esophageal and gastric/gastroesophageal junction adenocarcinoma (GEA), have a high mortality rate and present significant treatment challenges. Telisotuzumab adizutecan (Temab-A, ABBV-400), a novel antibody–drug conjugate targeting the c-Met protein (also known as MET protein), has shown encouraging results in patients with advanced GEA. Patients and Methods: This phase I, open-label, multicenter study assessed the safety, efficacy, and pharmacokinetics (PK) of Temab-A monotherapy (3 mg/kg every 3 weeks intravenously) in patients with advanced GEA. Patients ≥18 years of age with advanced/metastatic GEA who had received 1 to 2 prior systemic therapies were included. The primary objectives were the evaluation of safety, PK, and efficacy; efficacy endpoints included objective response rate (ORR), duration of response (DOR), progression-free survival (PFS), and overall survival (OS). c-Met expression and MET amplification were retrospectively assessed. Results: Forty-two patients with advanced GEA were enrolled; the median age was 60 years. The median follow-up duration was 12.6 months. All patients had one or more treatment-emergent adverse events (TEAE), with 88% experiencing grade ≥3 TEAEs. The most common hematologic TEAEs were anemia (67%), nausea (52%), and decreased appetite (36%). The ORR was 29%, the clinical benefit rate was 71%, and the median DOR was 4.2 months. The median PFS was 4 months, and the median OS was 5.8 months. Exploratory biomarker analyses showed ORR enrichment in patients with higher c-Met protein expression and MET focal amplification. Conclusions: Temab-A monotherapy demonstrated antitumor activity and a manageable safety profile in patients with advanced GEA. The findings support further clinical development of Temab-A, particularly in combination with other agents to improve outcomes for patients with 2L+ GEA.
BACKGROUND The International Academy of Cytology (IAC) recently introduced the Yokohama System (IAC-YS) for reporting breast fine-needle aspiration biopsy (FNAB) cytology. The Working Group on the Accuracy of Breast Fine-Needle Aspiration Cytology of the Japanese Society of Clinical Cytology aimed to categorize breast FNAB specimens according to the IAC-YS, assess the risk of malignancy (ROM) for each category, and evaluate the diagnostic yield of breast FNAB in Japan. METHODS Breast FNAB specimens obtained between January 2010 and December 2019 from nine cooperating facilities were retrospectively reclassified following the IAC-YS. The ROM for each category was calculated and compared with that using the conventional Japanese diagnostic system (CJS). Diagnostic yield was evaluated using a five-category approach to distinguish benign from malignant samples. RESULTS In total, 1727 samples from 1722 patients were distributed as follows: Category 1 (insufficient material), 21.3%; Category 2 (benign), 38.9%; Category 3 (atypical), 6.9%; Category 4 (suspicious for malignancy), 10.0%; and Category 5 (malignant), 23.0%. Histological follow-up was available for 856 cases (49.5%). The ROM was 13.1%, 4.8%, 26.9%, 84.3%, and 94.5% for Categories 1-5, respectively. CONCLUSIONS IAC-YS showed a higher proportion of cases of Category 1 and a lower proportion of cases of Category 3 than the CJS. Despite these differences, both systems were equivalent in their impact on daily medical care, although ROM differed for the content of Categories 1 and 3. Quality assurance parameters for our data based on IAC-YS are comparable to those of CJS.